Dinutuximab beta

DRUG13 trials

Sponsors

GPOH gGmbH, University Of Cologne, The University Of Birmingham, University of Birmingham, University Medicine Greifswald

Conditions

Alveolar RhabdomyosarcomaBone SarcomaEmbryonal RhabdomyosarcomaEwing SarcomaHigh-Risk NeuroblastomaHigh-risk GD2-Positive Ewing SarcomaHigh-risk NeuroblastomaNeuroblastoma

Phase 1

Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma

CompletedNCT05373901

BeiGeneHigh-risk Neuroblastoma

Start: 2022-06-07End: 2023-06-29Updated: 2024-10-04

Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma

RecruitingNCT06485947

Princess Maxima Center for Pediatric OncologyNeuroblastoma

Start: 2025-01-28End: 2031-12-01Target: 38Updated: 2025-07-08

International open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide in pediatric, adolescent, and adult patients with GD2-positive Ewing sarcoma

RecruitingCTIS2024-515245-42-00

GPOH gGmbHEwing Sarcoma

Start: 2025-04-24Target: 18Updated: 2025-05-16

International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma

Not yet recruitingNCT06839703

Prof. Dr. Dirk ReinhardtHigh-risk GD2-Positive Ewing Sarcoma

Start: 2025-03-01End: 2027-03-01Target: 18Updated: 2025-02-21

A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

RecruitingNCT07334301

University of BirminghamRelapsed Neuroblastoma

Start: 2024-11-11End: 2030-12-31Target: 160Updated: 2026-01-12

Phase 2

Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children

Active, not recruitingNCT02308527

University of BirminghamNeuroblastoma

Start: 2013-07-31End: 2026-02-28Updated: 2024-05-14

Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma

University Medicine GreifswaldNeuroblastoma

Start: 2015-03-27End: 2024-06-30Updated: 2021-10-04

Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma

SuspendedNCT05558280

Prof. Franca FagioliOsteosarcoma in Children

Start: 2023-11-30End: 2026-12-15Target: 22Updated: 2023-11-18

Quadruple Immunotherapy for Neuroblastoma

RecruitingNCT05754684

Hong Kong Children's HospitalNeuroblastoma Recurrent

Start: 2022-01-01End: 2025-12-31Target: 29Updated: 2025-09-15

BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma

Active, not recruitingCTIS2024-518931-12-00

The University Of BirminghamNeuroblastoma

Start: 2014-05-15Target: 122Updated: 2024-11-25

Phase 3

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

RecruitingNCT04221035

Gustave Roussy, Cancer Campus, Grand ParisHigh-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy

Start: 2019-11-05End: 2032-11-30Target: 800Updated: 2025-06-26

Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR

Not yet recruitingCTIS2024-517295-37-00

University Of Colognelow and intermediate risk neuroblastoma

Target: 280Updated: 2024-10-25

Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

RecruitingNCT06669013

N.N. Petrov National Medical Research Center of OncologyAlveolar Rhabdomyosarcoma, Bone Sarcoma, Embryonal Rhabdomyosarcoma

Start: 2021-05-20End: 2025-09-30Target: 40Updated: 2024-11-01

Related Papers

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial

Journal of Clinical Oncology2024-01-0817 citations

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study

British Journal of Cancer2023-10-1021 citations

Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).

Journal of Clinical Oncology2023-06-012 citations

BEACON-Immuno: Results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC–International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.

Journal of Clinical Oncology2022-06-0129 citations

Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma: A BEACON-Neuroblastoma biomarker study.

Journal of Clinical Oncology2022-06-012 citations

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

Frontiers in Pediatrics2022-03-1026 citations

Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): Results of the BEACON-Neuroblastoma randomized phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.

Journal of Clinical Oncology2019-05-203 citations

A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma - BEACON-Neuroblastoma, a European Innovative Therapies for Children with Cancer (ITCC) - International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.

Journal of Clinical Oncology2015-05-209 citations